An 8-week randomized, double-blind, placebo-controlled trial of 75 adults with subjective cognitive impairment found that Tremella fuciformis, at 600 or 1200 mg per day, produced greater improvement on a subjective memory complaint questionnaire than placebo, with no meaningful difference in adverse event rates between groups. That makes tremella one of the few functional mushrooms with actual human RCT data behind its cognitive reputation, not just preclinical mechanism studies.
The Human Trial: What It Actually Found
The 2018 trial, published in the Journal of Medicinal Food, randomized 75 participants with subjective cognitive impairment into a low-dose group (600 mg/day, n=30), a high-dose group (1200 mg/day, n=30), and a placebo group (n=15) for 8 weeks. Both tremella dose groups showed greater improvement on the subjective memory complaint questionnaire compared to placebo, and adverse event rates were statistically similar across all three groups — 40.4% in the high-dose group, 35.1% in the low-dose group, and 41.4% in placebo — supporting a favorable safety profile at both tested doses.
It's worth being precise about what this trial measured: subjective memory complaints and cognitive performance in people with mild, self-reported cognitive concerns, not a clinical dementia population. That's a meaningfully different population than trials targeting diagnosed cognitive decline, and the results should be read within that scope.
Reading the Trial's Design Honestly
Three design details deserve attention before anyone treats this as settled. The placebo arm held 15 people against 30 in each active arm, which is an unbalanced allocation that reduces the precision of every comparison against placebo. Eight weeks is short for a cognitive outcome. And the primary instrument was a subjective questionnaire — participants reporting how their memory felt — which is a legitimate endpoint for this population but is more susceptible to expectation effects than an objective performance battery.
None of that makes the result worthless. A properly randomized, double-blind, placebo-controlled design in humans is a genuinely higher tier of evidence than the cell and rodent work most mushroom cognitive claims rest on. It's one good small trial, and the appropriate response is interest rather than either dismissal or certainty.
The adverse event figures are arguably the more solid finding. Rates that sit within a few percentage points of placebo across both doses, including at 1200 mg/day, are a reasonable tolerability signal even in a trial this size.
Mechanism: NGF, CREB, and the Cholinergic System
Tremella's glucuronoxylomannan polysaccharide has been identified as having nerve growth factor (NGF)-stimulating activity, supporting neuronal survival and synaptic plasticity in preclinical research. NGF is the same broad category of neurotrophic signaling associated with lion's mane's hericenones and erinacines, though tremella and lion's mane act through distinct compounds rather than an identical mechanism.
A separate line of research points to activation of CREB (cAMP response element-binding protein) transcription and the cholinergic system — the same neurotransmitter system targeted by most approved medications for cognitive decline — as part of tremella's mechanism for supporting memory-related brain function.
There's an unresolved question sitting under all of this, and it's the same one that dogs every polysaccharide-based cognitive claim: glucuronoxylomannan is a large, water-soluble molecule that isn't expected to cross the blood-brain barrier intact. Any central effect therefore has to be indirect — mediated by gut-derived signals, immune messengers, or metabolites rather than by the polysaccharide itself reaching neurons. That's biologically plausible and increasingly well-described in the literature, but it isn't demonstrated for tremella specifically, and it's a bigger gap than most summaries admit.
Animal Research: Reversing Chemically Induced Memory Impairment
A 2012 study published in Behavioral Brain Research found that Tremella fuciformis enhanced neurite outgrowth in PC12 cells (a standard neuronal model cell line) and reversed memory impairment induced by trimethyltin — a neurotoxic compound used to model memory deficits — in rats, through activation of CREB transcription and the cholinergic system.
This animal and cell-culture research predates the 2018 human trial by six years and likely informed why researchers moved forward with testing tremella specifically for subjective cognitive impairment in people — a reasonably well-supported path from mechanism to human trial, compared to many mushroom cognitive claims that skip directly from cell-culture findings to consumer marketing without an intervening human study.
The trimethyltin model is worth understanding for what it does and doesn't represent. It produces acute, chemically induced hippocampal damage in a healthy young animal — a sharp, artificial insult rather than the slow, multifactorial changes of human cognitive ageing. Reversing that kind of damage is a real pharmacological result and a sensible screening test, but it isn't the same phenomenon as a middle-aged person noticing they misplace their keys more often.
How Tremella Compares to Lion's Mane for Cognitive Support
Lion's mane remains the more extensively studied mushroom for cognitive support, with its own separate human trial evidence in mild cognitive impairment discussed in the lion's mane cognitive research overview. Tremella's mechanism differs — its research centers more on subjective memory complaints, CREB activation, and cholinergic support, while lion's mane's better-known trial data centers on hericenone/erinacine-driven NGF synthesis in diagnosed mild cognitive impairment. The two aren't redundant; some people use them together as a combination rather than choosing one over the other.
| Tremella | Lion's mane | |
|---|---|---|
| Active compounds | Glucuronoxylomannan polysaccharides | Hericenones, erinacines |
| Blood-brain barrier | Indirect action assumed | Erinacines cross directly |
| Human trial population | Subjective cognitive impairment | Diagnosed mild cognitive impairment |
| Trial length | 8 weeks | 16 weeks and longer |
| Doses studied | 600–1200 mg/day | 1000–3000 mg/day |
| Volume of evidence | One notable RCT | Several RCTs |
Dosing, Format, and What to Look For
The trial doses — 600 and 1200 mg daily — are a reasonable anchor, and notably both worked, with no clear advantage to doubling. That argues for starting at the lower end. The trial used a tremella extract rather than raw dried mushroom, so a product's extraction ratio matters if you're trying to match what was tested; raw powder at 600 mg is not equivalent to 600 mg of the studied extract.
Look for a stated polysaccharide content and a product made from fruiting body rather than unspecified mycelium on grain, which dilutes polysaccharide content with residual starch. Eight weeks is the shortest period the human evidence covers, so that's a sensible minimum before judging whether it does anything for you. Our comparison of tremella powder and capsules covers the format trade-offs.
Who Should Be Careful
Tremella looked well tolerated in the trial, but a few situations call for a conversation with a clinician first. Tremella polysaccharides have shown blood-sugar-lowering activity in animal research, which is worth flagging if you take diabetes medication. Some fungal polysaccharides show anticoagulant activity in laboratory settings, so anyone on blood thinners should check. Mushroom allergies exist and are a straightforward contraindication.
Most importantly: new or worsening memory problems are a reason to see a doctor, not a reason to start a supplement. Subjective cognitive complaints have many causes — sleep disruption, thyroid dysfunction, depression, medication side effects, B12 deficiency — several of which are treatable and none of which tremella addresses.
Bottom Line
Tremella has genuine human RCT support for subjective memory complaints at 600-1200 mg/day over 8 weeks, which is a stronger evidence base than many mushroom cognitive claims can point to. It hasn't been tested in diagnosed dementia or more severe cognitive impairment populations, and an 8-week trial doesn't establish long-term effects beyond that window. Treat it as a promising, well-tolerated option with one good small trial behind it — not as a proven cognitive treatment, and not as a reason to postpone medical assessment of a real memory concern. For dosing guidance, see the tremella dosage guide, or browse our tremella mushroom.
This article is for informational purposes only. It is not intended to diagnose, treat, cure or prevent any disease. Consult a qualified healthcare professional before starting any supplement, particularly if you take medication for blood sugar or blood clotting, or if you have concerns about your memory.
Frequently Asked Questions
Is there human research on tremella and brain health?
Yes. A 2018 randomized, double-blind, placebo-controlled trial of 75 adults with subjective cognitive impairment found that 600 or 1200 mg/day of tremella improved subjective memory complaint scores over 8 weeks compared to placebo, with a safety profile comparable to placebo.
What is tremella's mechanism for supporting cognitive function?
Tremella's glucuronoxylomannan polysaccharide stimulates nerve growth factor (NGF) synthesis and has been shown in animal research to activate CREB transcription and the cholinergic neurotransmitter system. Because the polysaccharide isn't expected to cross the blood-brain barrier intact, any effect in people is likely indirect rather than the compound acting on neurons itself.
Does tremella work the same way as lion's mane for the brain?
No, though both target neurotrophic signaling. Lion's mane's hericenones and erinacines drive NGF synthesis and have separate human trial data in diagnosed mild cognitive impairment, while tremella's research centers on subjective memory complaints, CREB activation, and cholinergic system support. They're mechanistically distinct rather than duplicate claims.
How much tremella was used in the human cognitive trial?
The 2018 trial tested 600 mg/day and 1200 mg/day over 8 weeks, both showing greater improvement than placebo on subjective memory complaint measures, with similar rates of mild adverse events across all groups. Since both doses performed similarly, starting at the lower end is reasonable.
Can tremella help with diagnosed dementia or Alzheimer's disease?
The available human trial tested subjective cognitive impairment — self-reported memory concerns — not diagnosed dementia or Alzheimer's disease, so it doesn't directly establish benefit for those more severe conditions. Anyone with a diagnosed cognitive disorder should discuss supplement use with their physician rather than relying on this research alone.
Related Articles
- Tremella Dosage Guide
- Tremella Immune Support: The Polysaccharide Research
- Tremella Powder vs. Capsules
- Tremella and Anti-Aging Research
- Properties of Lion's Mane
Sources
- Ban S, Lee SL, Jeong HS, et al. Efficacy and safety of Tremella fuciformis in individuals with subjective cognitive impairment: a randomized controlled trial. Journal of Medicinal Food. 2018;21(4):400–407.
- Park KJ, Lee SY, Kim HS, et al. The neuroprotective and neurotrophic effects of Tremella fuciformis in PC12h cells. Mycobiology. 2007;35(1):11–15.
- Park HJ, Shim HS, Kim KS, Shim I. Tremella fuciformis enhances the neurite outgrowth of PC12 cells and restores trimethyltin-induced impairment of memory in rats via activation of CREB transcription and cholinergic systems. Behavioural Brain Research. 2012;229(1):82–90.
- Ma X, Yang M, He Y, Zhai C, Li C. A review on the production, structure, bioactivities and applications of Tremella polysaccharides. International Journal of Immunopathology and Pharmacology. 2021;35.